Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

SAC's Martoma wins delay of nine-year insider trading prison term

Published 11/04/2014, 06:54 PM
Updated 11/04/2014, 07:00 PM
© Reuters Martoma  exits the U.S. District Court for the Southern District of New York, following sentencing for insider trading, in Lower Manhattan

By Nate Raymond NEW YORK (Reuters) - Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, won an order Tuesday to delay the date he would begin serving a nine-year prison term for insider trading.

The 2nd U.S. Circuit Court of Appeals in New York agreed to delay Martoma's surrender date past Nov. 10 until after an appellate panel had considered his motion for bail pending appeal.

The decision came after Martoma, 40, hired a prominent lawyer, Paul Clement, to urge the court to consider his bail request after U.S. District Judge Paul Gardephe in Manhattan rejected a similar motion last month.

The 2nd Circuit scheduled arguments on Martoma's bail motion for Nov. 12, and directed prosecutors to respond to his request by this Friday.

Richard Strassberg, another lawyer for Martoma, declined comment. A spokeswoman for Manhattan U.S. Attorney Preet Bharara also declined comment.

A jury found Martoma guilty of three counts of conspiracy and securities fraud over a scheme that allowed SAC Capital to make profits and avoid losses of $275 million in trades in Elan Corp and Wyeth.

Martoma, who worked in SAC's CR Intrinsic Investors division, was accused of seeking out confidential information from doctors involved in a clinical trial of an Alzheimer's drug being developed by Elan and Wyeth.

Prosecutors said in July 2008, Martoma received a tip from a doctor about negative trial results for an Alzheimer's drug being developed by Elan and Wyeth.

The tip prompted SAC Capital to begin selling its $700 million position in Elan and Wyeth before the data was made public later that month, prosecutors said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Elan was acquired last year by Perrigo Company Plc, while Wyeth is now owned by Pfizer Inc.

The case followed a long-running insider trading investigation of SAC Capital. Eight employees have been convicted, and SAC last year agreed to pay $1.8 billion in criminal and civil settlements and plead guilty to fraud charges.

SAC has since changed its name to Point72 Asset Management, and the Stamford, Connecticut-firm was transformed into a family office managing Cohen's fortune.

The case is U.S. v. Martoma, 2nd U.S. Circuit Court of Appeals, No. 14-3599.

(Reporting by Nate Raymond in New York; Editing by David Gregorio)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.